

## Part I Epidemiology and Patients Views

- 1 Treatment of Dupuytren Disease in Different Countries: A Welcome Address from the President of IFSSH**  
Zsolt Szabó
- 2 The Epidemiology of Surgical Intervention for Dupuytren Contracture in England**  
Joseph J. Dias
- 3 Favorite Options of German Hand Surgeons in the Treatment of Dupuytren Disease**  
Bert Reichert and Magnus Baringer
- 4 Trends in Dupuytren Treatment in the United States**  
Scott Hadley, Emerson Floyd, John Zhao, and Philip Blazar
- 5 International Patient Survey (Part 1: Dupuytren Disease)**  
Wolfgang Wach and Gary Manley

## Part II Cellular and Extra-cellular Events, Pathogenesis

- 6 The Extracellular Matrix in Dupuytren Disease**  
David B. O’Gorman
- 7 Biomarkers of Postsurgical Outcome in Dupuytren Disease**  
Orla Jupp, Michael Pullinger, Tom Marjoram, Martin Lott, Adrian J. Chojnowski, and Ian M. Clark
- 8 Tumour Necrosis Factor as a Therapeutic Target in Dupuytren Disease**  
Jagdeep Nanchahal and David Izadi
- 9 Contraction Versus Contracture: Considerations on the Pathogenesis of Dupuytren Disease**  
Hanno Millesi
- 10 Controversy: The Contracture in Dupuytren Disease Is an Active Process**  
Jagdeep Nanchahal and David Izadi
- 11 Controversy: The Contracture in Dupuytren Disease Is a Passive Process**  
Charles Eaton

## Part III Genetics and Associations

- 12 Human Genetic Studies of Dupuytren Disease: A Primer**  
Roel A. Ophoff
- 13 Network Analysis and Fine-Mapping GWAS Loci to Identify Genes and Functional Variants Involved in the Development of Dupuytren Disease**  
Kerstin Becker, Juanjiangmeng Du, Peter Nürnberg, and Hans Christian Hennies

## Part IV Collagenase Injection

- 14 Collagenase Injection: Journey from Bench to Current Advanced Clinical Use**  
Lawrence C. Hurst, Marie A. Badalamente, Kerri Kulovitz, and Maria Relevo
- 15 Efficacy of Using Local Anesthesia Before Collagenase Injection in Reducing Overall Pain Experience in Patients Treated for Dupuytren Contracture: A Quasi-Randomized Study**  
Jesper Nordenskjöld, Eva Ahlgren, Johanna Waldau, Markus Waldén, and Isam Atroshi

- 16 **Effect of Delayed Finger Extension on the Efficacy and Safety of Collagenase Clostridium Histolyticum Treatment for Dupuytren Contracture**  
Gary M. Pess
- 17 **The Use of Dynamic Dorsal Splint for Dupuytren Rehabilitation After Collagenase Injection**  
Massimo Corain, Roberta Sartore, and Roberto Adani
- 18 **Prospective Multicenter, Multinational Study to Evaluate the Safety and Efficacy of Concurrent Collagenase Clostridium Histolyticum Injections to Treat Two Dupuytren Contractures in the Same Hand**  
Marie A. Badalamente, Lawrence C. Hurst, R. Glenn Gaston, Richard A. Brown, James P. Tursi, and Ted Smith
- 19 **Collagenase: What We May Never Know (A Discussion)**  
David Warwick
- 20 **Controversy: Comparison of the Literature on PNF and CCH as Minimally Invasive Treatment Options for Dupuytren Disease**  
Paul M.N. Werker

## **Part V Percutaneous Needle Fasciotomy (PNF)**

- 21 **Tips and Pearls for PNF and Collagenase: A Ten-Year Personal Experience**  
Gary M. Pess
- 22 **Clinical Results of Percutaneous Needle Fasciotomy for Dupuytren Contracture: Are There Significant Correlations Between Preoperative Dupuytren Diathesis Score and Contracture Recurrence?**  
Yoshihiro Abe
- 23 **Effectiveness of Percutaneous Needle Fasciotomy for Second or Higher Recurrence in Dupuytren Contracture**  
Margot A. Vlot and Paul M.N. Werker
- 24 **Controversy: How to Treat Severe PIP Contractures? - Collagenase Treatment**  
Clayton A. Peimer
- 25 **Controversy: How to Treat Severe PIP Contractures? - Surgical Correction**  
Caroline Leclercq

## **Part VI Assessment**

- 26 **Correlation of Function with Deformity in Dupuytren Disease: The Condition-Specific Southampton Scoring Scheme Outperforms the Generic QuickDASH**  
David Warwick
- 27 **Tonometry as an Outcome Measure for the Treatment of Early Dupuytren Disease**  
Catherine Ball, David Izadi, and Jagdeep Nanchahal
- 28 **The Intra- and Interobserver Agreement on Diagnosis of Dupuytren Disease, Measurements of Severity of Contracture, and Disease Extent**  
Dieuwke C. Broekstra, Rosanne Lanting, Edwin R. van den Heuvel, and Paul M.N. Werker
- 29 **Variation in Range of Movement Reporting in Dupuytren Disease**  
Anna L. Pratt and Catherine Ball
- 30 **Use of Digital Photography and Mobile Device Application to Assess Finger Deformity in Dupuytren Disease**  
Daniel Gheorghiu and Vijay Bhalai
- 31 **Application for Determining the Degree and Diagnose Code of Dupuytren Contracture by Digital Photography**

## **Part VII Comparative Studies and Economics**

### **32 Treatment of Dupuytren Disease: Where Are We Now?**

David Elliot

### **33 Steroid Injection and Needle Aponeurotomy for Dupuytren Disease**

Catherine McMillan and Paul Binhammer

### **34 Minimally Invasive Treatment of Dupuytren Contracture: Collagenase Versus PNF**

Eva-Maria Baur

### **35 Comparative Effectiveness of Collagenase Injection for Dupuytren Contracture**

Chao Zhou, Steven E.R. Hovius, Harm P. Slijper, Reinier Feitz, Christianne A. Van Nieuwenhoven, Hanneke J. Pieters, and Ruud W. Selles

### **36 Short-Term Cost-Utility Analysis of Collagenase Versus Fasciectomy for Dupuytren Contracture**

Rafael Sanjuan-Cervero, Nuria Franco-Ferrando, Jaime E. Poquet-Jornet, Francisco J. Carrera-Hueso, and Pedro Vazquez-Ferreiro

### **37 An Easy Way for Clinical Validation of the Pharmacoeconomic Model in Dupuytren Disease**

Rafael Sanjuan-Cervero, Nuria Franco-Ferrando, Jaime E Poquet- Jornet, Francisco J Carrera-Hueso, and Pedro Vazquez-Ferreiro

## **Part VIII Surgical Techniques and Recurrence**

### **38 Preliminary Soft-Tissue Distraction with the Digit Widget™ in the Management of Advanced Dupuytren Contracture at the Proximal Interphalangeal Joint**

Solomon Azouz, Atanu Biswas, and Anthony Smith

### **39 Is Recurrence After Treatment Predictable? Risk Factors in Dupuytren Disease**

Maarten Van Nuffel and Ilse Degreef

### **40 Is Recurrence of Dupuytren Disease Avoided in Full-Thickness Grafting?**

Ilse Degreef and Marieke Torrekens

### **41 The Use of Acellular Dermal Matrix in Dupuytren Disease**

Gloria R. Sue and Deepak Narayan

### **42 Indications of the Continuous Extension Technique (TEC) for Severe Dupuytren Disease and Recurrences**

Jane C. Messina and Antonino Messina

### **43 Experience in Treating Patients with Stage IV of Dupuytren Contracture (PNF vs. Fasciectomy)**

Andrei Zhigalo, Alexander Silaev, Victor Morozov, and Vitaliy Chernov

### **44 Controversy: Splinting for Dupuytren Contracture**

Adrian Chojnowski, Wolfgang Wach, and Ilse Degreef

## **Part IX Related Diseases and Other Treatments**

### **45 Introduction to Radiation Biology When Treating Hyperproliferative Benign Diseases**

Franz Rödel and M. Heinrich Seegenschmiedt

### **46 Review of Radiation Therapy for Palmar and Plantar Fibromatosis (Dupuytren and Ledderhose Disease)**

M. Heinrich Seegenschmiedt, Karin Piefel, and Thomas Schneider

### **47 Splinting as a Therapeutic Option in Dupuytren Contractures**

- 48 Treatment Options for Patients with Adhesive Capsulitis (Frozen Shoulder)**  
Marie A. Badalamente
- 49 International Patient Survey (Part 2: Ledderhose Disease)**  
Anne Schurer, Gary Manley, and Wolfgang Wach
- 50 Peyronie Disease**  
Mels van Driel

## **Part X Future Paths of Research**

- 51 The Next Stage of Clinical Dupuytren Research: Biomarkers and Chronic Disease Research Tools**  
Charles Eaton
- 52 The Future of Basic Dupuytren Disease Research**  
David B. O’Gorman
- 53 How Should We Fund Basic Research of Dupuytren Disease?**  
Dominic Furniss
- 54 Clinical Research: International Collaboration to Execute High-Powered Clinical Trials**  
Marie A. Badalamente
- 55 Patient-Rated Outcome Measures and Dupuytren Contracture**  
Joseph J. Dias
- 56 IDDB: An International Research Database of the Dupuytren Foundation**  
Charles Eaton
- 57 International Clinical Research – The Australian Perspective: A Personal View**  
Stephen G. Coleman
- 58 Open Questions and Potential Answers**  
Charles Eaton